Abstract
Introduction
The treatment of opiate abusers by substitution was introduced fairly late in France. Methadone, already widely used in other countries, became available in January 1995 The risk of overdose when this substitute drug is misused is well known, causing the public authorities to control its dispensing very strictly.
Buprenorphine high dosage becam e available in 1996. This synthetic morphinom imetic 1 is a partial mu receptor agonist and a kappa receptor antagonist. It binds to morphine receptors, and has a duration of action of at least 24 hours. 2 It is dispensed as a sublingual tablet to be taken once a day. It has been reported to have no euphoric effects 1 and display an agonist activity ceiling, 3 with no increased bene® t on increasing the dosage. 4 The withdrawal syndrome produced if the treatment is suddenly discontinued appears to be less rapid and less intense than with a pure agonist such as morphine or methadone. 5 In France it is used as an analgesic under the trade name Temgesic at dosages of 0.2 mg. For substitution treatm ent, a high dosage form is used, marketed under the trade name Subutex. The dosages for substitution are between 2 mg and 8 mg.
Because of the ceiling effect this drug is considered particularly safe and has therefore become widely available in general medical practice. It is dispensed at a ª moderate level of controlº . Any physician may prescribe buprenorphine in a counterfoil book for up to 28 days. Any pharm acist may supply it. Urine assays are not mandatory. However, it is recommended that the prescribing physician seek the advice of physicians in specialized drug abuse treatment centres, and experienced general physicians, via a collaborative network. 6, 7 In December 1996, 29 000 patients were being treated with buprenorphine. Some drug abusers, and indeed some physicians, have not been complying with the approved practice for prescribing and using this drug. This paper reports the implication of a buprenorphine± benzodiazepine association in six deaths of known abusers.
M ethods

Subjects
Six suspect deaths among abusers were reported in the period between November 1996 and March 1997 (three of them in Auvergne and three in Alsace). As very few laboratories are able to assay buprenorphine, analyses have not been conducted on all the overdoses of this period.
Six autopsies were ordered for legal purposes to establish cause of death. The observations comprise the inform ation in the police report and information obtained, when available, from drug abuse care workers. None of these cases was being followed regularly, and none had an organized care program me.
C ase 1. M ale, aged 26 years, known heroin addict, found dead on his bed. Near the body were found a used insulin syringe, an empty blister pack of Subutex 8 m g and a teaspoon containing a white residue. Numerous other psychotropic drugs (benzodiazepines) were found in the¯at. Post-m ortem examination showed no signs of violence, numerous venous injection points inside the left elbow, signs of severe asphyxia (cyanosis, multivisceral congestion, pulmonary oedema, Tardieu' s spots).
The evidence suggested that buprenorphine had been injected intravenously from crushed Subutex tablets; injection mark inside the elbow, syringe, spoon, Subutex blister pack close to the body, very low level of buprenorphine in the stomach contents, white residue shown to contain a high concentration of buprenorphine with no associated drug. The death followed a group injection, acknowledged by the other people involved. Evidence of massive concomitant use of Tranxene (dipotassium chlorazepate) and Rohypnol (¯uni-trazepam) by oral route.
Toxicological analyses
The following post-mortem toxicological analyses were conducted on these six cases.
First, the blood and urine underwent triple exhaustive screening by immunochem ical methods (EMIT on Syva ETS Plus, FPIA on Abbott TD x), high perform ance liquid chrom atography with diode detection (HPLC/DAD) and gas phase chromatography coupled with m ass spectrom etry (GPC/M S). The combination of all these methods covers several thousand potentially toxic com pounds, and allows identi® cation and assay of narcotics (opiates and derivatives, cocaine, amphetamines and derivatives, etc.) together with all the psychotropes in the pharmacopeia (barbiturates, benzodiazepines, antidepressants, neuroleptics, carbamates, etc.). Other substances sought included ethanol, volatile solvents and cyanides by gas phase chromatography, carbon monoxide by carboxim etry, digitalis glycosides by high performance liquid chromatography coupled to mass spectrom etry (HPLC/MS) and arsenic and thallium by atomic absorption spectrometry.
Secondly, buprenorphine and its m ain metabolite, norbuprenorphine, were analysed and quanti® ed in all the autopsy sam ples (blood, urine, stomach contents, liver, brain, kidney, heart muscle, etc.) by means of an HPLC/MS method already described elsewhere. 8 Unlike m ost opiates (morphine, codeine, etc.) and opiate-like agents (dextropropoxyphene, methadone), buprenorphine is particularly dif® cult to characterize in biological m edia, and so a large num ber of analytical procedures were used. Radio-immunological assay (RIA) is extremely sensitive, but it is dif® cult to use routinely and can be adversely affected by interference. Above all, it does not allow separate assay of buprenorphine and its m etabolite (due to cross-reactivity). 9, 10 In addition, GPC/M S, although a favourite method in forensic toxicology, is inappropriate here due to the high therm al lability of buprenorphine. 10, 11 On the other hand, HPL C/M S offers a good comprom ise; simplicity and ease of use, and high sensitivity and absolute speci® city. Our m ethod was initially designed for biological¯uids and hair, 8 but proved suitable for homogenates of viscera after triple extraction, m ade necessary by the com plexity of the tissues. Assay of benzodiazepines in the post-m ortem samples was carried out by HPL C/DAD as described previously elsewhere. 12, 13 R esults Benzodiazepine± buprenorphine associations were found in every case (norbuprenorphine was found less systematically). No other substance that could account for the death was found (e.g. illicit poisons, psychotropics, other drugs).
Blood assays
The blood concentrations of buprenorphine were in the therapeutic range in observations 1, 2 and 6 (2.5, 1.1 and 1.7 ng/ml), and higher than therapeutic in the other three (9.0, 12.6, 17.7 ng/ml) relative to known values in nonabusers.
The exhaustive screening detected no traces of opiates (m orphine, codeine, 6-m onoacetylmorphine, etc.) in the post-mortem blood.
In contrast, all the subjects displayed benzodiazepine at therapeutic-range levels for both dem ethyldiazepam and 7-amino¯unitrazepam (metabolite of¯unitrazepam , classically found alone in post-mortem examinations, as unitrazepam cannot usually be assayed).
Finally, in subjects 2, 3 and 4, a moderate ethanol level was found (the ante-m ortem origin of which is arguable in cases 2 and 3, given the state of putrefaction of the bodies).
Tissue assays
The levels of buprenorphine measured in the brain, kidney and liver were, respectively, 3± 12 times, 1± 33 times and 2± 28 times higher than in the blood.
D iscussion
The discussion will address two issues: (1) analysis of our data concerning blood and tissues concentrations; and (2) assessment of the risk of respiratory depression by overdose induced by buprenorphine, alone or associated with benzo- diazepines, according to the adm inistration route, and in relation to pharmacological, toxicological and narcotic parameters. In all the cases the blood concentrations of buprenorphine were fairly low. In general, neither the ef® ciency nor the central depressor effects of buprenorphine are closely correlated with plasma levels. 14± 19 This is accounted for by the high lipophilicity of the m olecule, and its strong persistent binding to opiate receptors. In the rare cases of side effects when assays were carried out, 14, 15 the plasm a concentrations were in the therapeutic range. Given its high lipophilicity, buprenorphine is distributed almost entirely in the extravascular volum e, irrespective of its mode of administration. 20 Consequently, its tissue concentrations were m arkedly higher than its blood levels. The levels found in the stomach contents in cases 4 and 5 suggest a massive sublingual or oral dose, although there has been no study of buprenorphine concentrations in stom ach contents after oral, sublingual or parenteral adm inistration. Similarly, the breakdown kinetics of buprenorphine in gastric acid medium are unknown. The interpretation of these blood concentrations m ust allow for the possibility of postmortem redistribution processes. 21 Such redistribution can be especially marked for lipophilic com pounds with high distribution volumes (i.e. with strong tissue binding). Their massive release from viscera after death can cause a local rise in blood levels in the adjoining vessels. This can sometimes result in spuriously high values if assays are performed on samples taken from these areas. In our six observations, despite the appreciable lipophilicity of buprenorphine, any such redistribution could only have been at most of m inor importance, because blood samples were taken not only from the heart, but also from the periphery (i.e. femoral artery) at a point not prone to redistribution effects, according to the consensus adopted by the French Association for Further Training in Forensic Medicine. 22, 23 The heart blood samples were used for the qualitative screening of drugs and narcotics, and the peripheral sam ples for quanti® cation. These precautions ensured that the post-mortem blood levels were close to those in the blood stream at the tim e of death. The risks incurred by the m isuse of Subutex seem to arise through a combination of two practices: (1) improper use of the tablet form for intravenous administration or massive oral doses; and (2) association of other psychotropic agents, especially benzodiazepines.
The ceiling effect of buprenorphine is docum ented in clinical practice. 3, 4, 25 Cases 4 and 5 suggest that in certain situations (associations with other CN S antidepressants, individual sensitivity) a m assive dose of buprenorphine by sublingual and/or oral route m ay lead to a true overdose, despite the ceiling effect and the poor enteral bioavailability of this drug. The literature reports som e cases of severe respiratory depression after proven absorption of buprenorphine by the sublingual route. 15, 36, 54 These pharmacological ® ndings are to be interpreted with caution, since the pharmacological effects of morphine agonists are not the sam e in abusers and non-abusers.
The recording of six deaths linked to misuse of associations of benzodiazepines with high-dose buprenorphine prompts us to m ake a number of recomm endations:
· It is important to evaluate risks as precisely as possible by carrying out system atic blood assays of buprenorphine in every case of death of a drug abuser when drug misuse can be suspected.
· There is a need to improve pharmacological knowledge concerning the effects of benzodiazepine± buprenorphine associations.
· Information for both prescribers and users needs to be updated.
· In the light of the above, it m ay be important to review the provisions for dispensing high dose buprenorphine.
These cases were drug abusers who were not included in well-organized care programmes, and who were deliberately misusing prescriptions (a relatively common occurrence). However, the demonstration of potentially lethal effects of the buprenorphine± benzodiazepine association challenges the purported harmlessness of buprenorphine.
